7Marbeuf Gueye C, Salerno M, Quidu P, et al. Inhibition of the Pglycoprotein and multidrug resistance protein - mediated efflux of anthracyclines and calceina cetoxymethyl ester by PAK-104P[J]. Eur J Pharmacol, 2000,391(3):207-216.
8Motoji T, Motomura S, Wang YH. Multidrug resistance of acute leukemia and a strategy to overcome it[J].Int J Hematol, 2000, 72(4):418-424.
9Swannie HC, Kaye SB. Protein kinase C inhibitors[J]. Curr Oncol Rep, 2002, 4(1):37-46.
10Komuro Y, Udagawa Y, Susumu N, et al. Paclitaxel and SN-38 overcome cisplatin resistance of cell lines by down - regulating the influx and efflux system of cispaltin[J]. Cancer Res, 2001,92(11):1242-1250.
8Chu E, Drake JC, Koeller DM.Induction of thymidylate synthase associated with multidrug resistance in human breast andcolon cancer cell lines [ J ]. Mol Pharmacol, 1991,39:136.
2Agarwala SS, Kirkwood JM, Gore M, et al.Temozolomide for the Treatment of Brain Metastases Associated with Metastatic Melanoma.A Phase Ⅱ Study[J].Journal of clinical Oncology,2004,22(11):2101-2107.
3Ridolfi R, Romanini A, Sileni VC, et al. Temozolomide and interferonalpha in metastatic melanoma:a phaseⅡstudy of the ltalian melanoma lntergroup [J].Melanoma Res,2004,14(4)295-299.
4WenJen Hwu, Eric Lis, Jennifer H.Menell, et al. Temozolomide Plus Thalidomide in Patients with Brain Metastases from Melanoma[J]. Cancer, 2005,103(12),2590-2597.
5Middleton MR, Lunn JM, Morris C, et al. O6-Methylguanine DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma[J]. Br J Cancer, 1998,78(9):1199-1202.
6Juillerat A, JuilleratJeanneret L.Salkylthiolation of O6-methylguanineDNAmethyltransferase (MGMT) to sensitize cancer cells to anticancer therapy [J]. Expert Opin Ther Targets,2007,11(3):349-361.
7Quirt I, Verma S, Petrella T, et al. Temozolomide for the treatment of metastatic melanoma[J]. Oncologist,2007 ,14(1): 27-33.
8Gogas H, Polyzos A, Stavrinidis I, et al. Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group [J]. Annals of Oncology,2006,17(12):1835-1841.
9Wen-Jen Hwu, Katherine S, ennifer H, et al. Phase II study of temozolomide plus pegylated interferon-α-2b for metastatic melanoma[J]. Expert Opin Ther Targets, 2007,11(3):349-361.
10Ridolfi R, Romanini A, Sileni VC,et al. Temozolomide and interferonalpha in metastatic melanoma: a phase II study of the Italian Melanoma Intergroup[J]. Melanoma Res,2004,14(4):295-299.